Moderate to high levels of pre‐treatment HIV drug resistance in KwaZulu‐Natal Province, South Africa Benjamin Chimukangara, 1, 2, 3 Ayesha BM Kharsany, 2 Richard J Lessells, 1 Kogieleum Naidoo, 2 Soo‐Yon Rhee, 4 Justen Manasa, 5 Tiago Gräf, 1 Lara Lewis, 2 Cherie Cawood, 6 David Khanyile, 6 Karidia Diallo, 7 Kassahun A Ayalew, 7 Robert W Shafer, 4 Gillian Hunt, 8, 9 Deenan Pillay, 10, 11 Salim Karim Abdool, 2 and Tulio de Oliveira 1, 2 Affiliations: 1 KwaZulu‐Natal Research Innovation and Sequencing Platform (KRISP), School of Laboratory Medicine and Medical Sciences, University of KwaZulu‐Natal, Durban, South Africa 2 Centre for the AIDS Programme of Research in South Africa (CAPRISA), Doris Duke Medical Research Institute, Nelson R Mandela School of Medicine, University of KwaZulu‐ Natal, Durban, South Africa 3 Department of Virology, National Health Laboratory Service, University of KwaZulu‐Natal, Durban, South Africa 4 Department of Medicine, Stanford University, Stanford, California, United States of America 5 Department of Medicine, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe 6 Epicentre AIDS Risk Management (Pty) Limited, Paarl, Cape Town, South Africa 7 Centers for Disease Control and Prevention (CDC), Pretoria, South Africa Downloaded by UCL /SWETS/28908077 from www.liebertpub.com at 11/26/18. For personal use only. 8 Centre for HIV and STIs, National Institute for Communicable Diseases (NICD), Johannesburg, South Africa 9 Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa 10 Africa Health Research Institute, KwaZulu‐Natal, South Africa 11 Division of Infection and Immunity, University College London, London, United Kingdom AIDS Research and Human Retroviruses Moderate to high levels of pre‐treatment HIV drug resistance in KwaZulu‐Natal Province, South Africa (DOI: 10.1089/AID.2018.0202) This paper has been peer‐reviewed and accepted for publication, but has yet to undergo copyediting and proof correction.
